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We have identified an 85-kDa outer membrane protein that is expressed by all tested strains of Haemophilus
ducreyi. Studies of related proteins from other pathogenic bacteria, including Haemophilus influenzae, Pasteu-
rella multocida, Neisseria gonorrhoeae, Neisseria meningitidis, and Shigella dysenteriae, suggested a role for these
proteins in pathogenesis and immunity. In keeping with the first such described protein from Haemophilus
influenzae type B, we termed the H. ducreyi protein D15. The gene encoding the H. ducreyi D15 protein was
cloned and sequenced, and the deduced amino acid sequence was found to be most similar to sequences of the
D15-related proteins from other Pasteurella spp. The arrangement of the flanking genes was similar to that of
H. influenzae Rd and suggested that D15 was part of a multigene operon. Attempts to make a null mutation of
the D15 gene were unsuccessful, paralleling results in other D15 gene studies. Overexpression of H. ducreyi D15
in Escherichia coli resulted in a source of recombinant D15 (rD15) from which it was readily purified. rD15 was
immunogenic, and it was found that immunization of rabbits with an rD15 vaccine preparation conferred
partial protection against a virulent challenge infection. Antisera to an N-terminal peptide recognized all tested
strains of H. ducreyi.
Haemophilus ducreyi is the etiologic agent of chancroid, a
sexually transmitted genital ulcerative disease that is prevalent
in Africa, Asia, and certain other developing countries (1, 54).
Recently, several studies have demonstrated a role for chan-
croid as an important independent risk factor for the hetero-
sexual transmission of human immunodeficiency virus (23, 28,
54). Reinfection with H. ducreyi occurs after natural (54) or
experimental (6) human infection, suggesting that infection
does not confer immunity. No vaccine or practical field diag-
nostic test currently exists for chancroid.
H. ducreyi is an obligate human pathogen. The bacterium is
difficult to grow in vitro, where it requires the essential nutrient
heme, presumably supplied in vivo by host hemoglobin, heme,
or catalase (19). The ability of H. ducreyi to resist the bacteri-
cidal nature of complement-intact normal human serum and
its partial resistance to phagocytic killing in vitro may partially
explain its ability to survive in chancroid lesions, which contain
these host defenses mechanisms (18, 32, 35–37).
Because of the importance of chancroid as a risk factor for
the acquisition of human immunodeficiency virus, recent stud-
ies from several laboratories have begun to reveal potential
virulence factors and potential vaccine candidates of H. du-
creyi. Several outer membrane proteins have been character-
ized at the molecular level, including a hemoglobin receptor
(15, 17), a pilin protein (8), a lipoprotein (26; T. Hiltke, C. Lau,
S. Gurunathan, A. Juarez, A. Campagnari, and S. Spinola,
presented at the 94th General Meeting of the American Soci-
ety for Microbiology, Las Vegas, Nev., 1994) two OmpA-like
proteins (30), a P6-like protein (49), a heme receptor (51), and
a protein required for expression of serum resistance, termed
DsrA (18). Three secreted proteins likely to be involved in
virulence include a hemolysin (2, 14, 38–40, 53), a cytolethal
distending cytotoxin (9, 41), and two filamentous hemaggluti-
nin-like proteins termed LspA1 and LspA2 (55). A cytoplasmic
superoxide dismutase (45, 46), an enzyme involved in resis-
tance to polymorphonuclear leukocyte killing, has been found
to be required for full virulence expression in an animal model
(47). For most of these putative virulence factors, separate
isogenic mutants, each lacking one factor, have been con-
structed and tested in the human challenge model of H. ducreyi
infection. To date only the hemoglobin receptor mutant (4),
the P6 mutant (5), and the dsrA mutant (6a) have been found
to be highly attenuated.
Flack et al. first reported an 85-kDa outer membrane pro-
tein which is highly conserved in typeable and nontypeable
strains of H. influenzae (21). They termed it D15. Since then,
several studies of animal models of H. influenzae infection
demonstrated that D15 confers protection against homologous
strains (33, 52, 56); in one study, D15 was protective against
heterologous strains (33). Similarly, Oma 87, a highly related
protein of Pasteurella multocida, has been shown to elicit pro-
tection in an animal model of infection (44). Since the D15 and
D15-like proteins had previously been shown to elicit protec-
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tive immunity in these other systems, we sought evidence for
D15-induced immunity in the H. ducreyi system.
We report here the cloning and sequencing of the gene
encoding the D15 protein of H. ducreyi. Recombinant D15
(rD15) was overexpressed and purified from Escherichia coli
for the purpose of immunobiological studies. We show that
rD15 is immunogenic in rabbits and that D15 shares certain
attributes of successful vaccines.
MATERIALS AND METHODS
Strains and media. We used the extensively characterized H. ducreyi strain
35000 for most assays. Other strains used were previously described by us (15) or
others (3, 14, 35). The strains used in Western blots are listed in the legend to
Fig. 5. An additional 26 strains from a characterized panel (14) were used in
other Western blots but are not listed because there was no difference in reac-
tivity or mobility (data not shown). For routine growth, H. ducreyi was main-
tained on chocolate agar plates prepared by the UNC Hospitals media lab. The
basal medium for chocolate agar was Mueller-Hinton agar containing 1% Iso-
VitaleX and 1% autoclaved hemoglobin. The E. coli strains were DH5aMCR
and BL21(DE3)pLysS. E. coli strains harboring plasmids were grown on Luria-
Bertani agar or in Luria-Bertani broth containing appropriate antibiotics. The
antibiotics used for E. coli included ampicillin (100 mg/ml), chloramphenicol (30
mg/ml), kanamycin (30 mg/ml), and rifampin (200 mg/ml). Outer membranes
were isolated as previously described (15).
N-terminal amino acid sequencing and antipeptide antibody production. An
approximately 85-kDa D15 protein from H. ducreyi strain 35000 was subjected to
Edman degradation using an outer membrane preparation electroblotted from a
sodium dodecyl sulfate (SDS)–10% polyacrylamide gel to a polyvinylidene di-
fluoride membrane as previously described (15). The sequence APFVLKDIRIDG
VQTETNA was obtained. This sequence was determined by the UNC/PMBB
MicroProtein Chemistry Facility (Program in Molecular Biology and Biotech-
nology, University of North Carolina at Chapel Hill).
A predicted antigenic peptide derived from the N-terminal sequence was
synthesized by standard fluoroenylmethoxycarbonyl chemistry by the UNC/
PMBB MicroProtein Chemistry Facility. The peptide sequence was CGG
KDIRIDGVQTETGNA. The three underlined residues are not part of the D15
protein sequence (see above). The initial C functioned for sulfhydryl coupling,
and the following GG functioned as a spacer. After peptide purification by
reverse-phase high-performance chromatography, the sequence was confirmed
by fast atom bombardment-mass spectrophotometry. The peptide was conju-
gated to keyhole limpet hemocyanin, and rabbits were immunized a total of five
times at 3-week intervals with 0.5 mg of peptide conjugate per immunization.
Freund’s complete adjuvant was used for the first immunization; Freund’s in-
complete adjuvant was used with succeeding doses. Immune serum was affinity
purified using D15 peptide immobilized on a thiopropyl-agarose column as
previously described (15).
Initial PCR and cloning of the gene encoding the D15 protein (pUNCH 1215).
Initial attempts to obtain genomic plasmid clones using the antipeptide immu-
noglobulin G (IgG) described above in an expression library were unsuccessful.
Similarly, we were unable to obtain clones using degenerate oligonucleotide
probes. We speculated that production of D15 with a leader sequence might be
toxic to the host E. coli, as had been our experience with several other outer
membrane proteins. Therefore, we used a PCR strategy to amplify a 2.4-kb
product lacking the putative leader sequence and cloned it into pCRII. To
initially confirm that the PCR was correct, inserts were subcloned from pCRII
into an expression system (pET30). After induction with isopropyl-b-D-thioga-
lactopyranoside (IPTG), recombinants expressing D15 protein were identified in
Western blots with the anti-synthetic peptide IgG described above. Subsequently,
sequencing (see below) confirmed that we had cloned D15. The 59 degenerate
oligonucleotide (59GGATCCGAATTCGCICCITTYGTIGTIAARGAYATHMG)
was deduced from the N-terminal amino sequence of H. ducreyi and H. influenzae
Rd DNA and amino acid sequences. The first H. ducreyi codon began at the first
amino acid (alanine) of the mature protein. The 39 degenerate amplimer (59C
GCCGGCGTTCGACCICCIATISWRAAYTGKAAYTGYTC) was derived from
the sequence of the H. influenzae Rd D15 amino acid sequence and encoded the
terminal phenylalanine and stop codon of D15. The underlined bases indicate
restriction sites or other bases not part of the D15 sequence. The PCR conditions
were 94°C for 1 min, 42°C 1 min, and 68°C for 4 min, each for 30 cycles. Ready
To Go PCR tubes (Amersham Pharmacia Biotech Inc.) were used for PCR, and
the final magnesium concentration was adjusted to 3.75 mM. The initial expres-
sion clone, designated pUNCH 1215, expressed full-length immunoreactive pro-
tein (data not shown).
Genomic cloning of D15 and its flanking DNA. Since pUNCH 1215 was
constructed with degenerate amplimers (including sequence derived from H.
influenzae), it was imperfect. We obtained genomic clones in order to determine
the correct H. ducreyi sequence, to understand the gene arrangement and orga-
FIG. 1. Restriction map of the H. ducreyi D15 region and the clones
described in this study. The lower portion shows the corresponding H.
influenzae region. A total of 14 kb of contiguous genomic DNA from
H. ducreyi is contained within pUNCH 1227 and pUNCH 1233. The
coding sequence of the mature form of rD15 found in pUNCH 1215
and 1235 is indicated (the hexahistidine leader present in pUNCH
1215 and 1235 is not shown). HI# indicates the H. influenzae ORF
number and gene designation. The cross-hatched box indicates the H.
ducreyi sequence presented in Fig. 2. The broken lines indicate addi-
tional flanking sequences not shown.

































Sham 105 14 5 61.9 10.1 6 4.2 51.4 6 6.3 4 6 0 13 (93) 27/28 (96) 12 6 3.2
104 14 4.2 6 2.1 10.7 6 2.8 47.2 6 8.8 4 6 0 14 (100) 28/28 (100) 11.5 6 3.3
103 14 3.7 6 2 9.1 6 2.6 30.4 6 6.9 3.5 6 0.5 6 (43) 17/28 (61) 4.7 6 3.4
rD15 105 13 7.6 6 2.8a 6.8 6 2.7a 43.9 6 13 3.8 6 0.3 9 (69) 21/26 (81) 7.9 6 4.5b
104 13 6.1 6 2.5a 8.5 6 3.2 40.4 6 13 3.8 6 0.6 10 (77) 22/26a (85) 8.5 6 4
103 13 5.8 6 2.4a 7.4 6 3.9 24 6 14.2 3.3 6 0.7 4 (31) 10/26 (38) 3.3 6 4.1
rFetA 105 8 7.1 6 4 9 6 4.1 52.6 6 14 4 6 0 8 (100) 16/16 (100) 11.8 6 3.7
104 8 5.7 6 2 6.8 6 3.2a 46 6 10 4 6 0 8 (100) 16/16 (100) 11.4 6 3.2
103 8 6 6 2.7a 7.8 6 4.1 29.5 6 12 3.5 6 0.7 4 (50) 10/16 (63) 5.9 6 4.7
a P , 0.05; one-way repeated measures analysis of variance.
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nization of the D15 region, to identify promoter sequences, and to determine the
structure of the leader sequence. An EcoRI site was identified in the middle of
the H. ducreyi D15 gene from pUNCH 1215 (Fig. 1) and exploited in the
construction of D15 genomic clones. Using both halves of pUNCH 1215 as
probes in Southern blots, we identified upstream and downstream genomic
EcoRI fragments of 5.5 and 8.0 kb, respectively. Appropriate size-selected DNA
fragments were gel purified and ligated to alkaline phosphatase-treated
pMCL210 vector (36). Colony hybridizations were performed using the appro-
priate pUNCH 1215 EcoRI probe fragment (Genius protocol; Boehringer
Mannheim). The upstream genomic clone (pUNCH 1227 [Fig. 1]) was initially
confirmed by internal PCR using primers derived from pUNCH 1215 sequence
(data not shown). The downstream genomic clone (pUNCH 1233) was initially
confirmed by Southern blotting (data not shown).
DNA sequencing. Both strands of the D15 gene in pUNCH 1215 were se-
quenced. Comparison to D15-like genes from other bacteria suggested that we
had indeed cloned the D15 gene of H. ducreyi. Initial sequencing of the genomic
clones pUNCH 1227 and pUNCH 1233 was done on single strands only. Any
discrepancies between pUNCH 1215 and the genomic clones were resolved by
double-stranded sequencing the relevant regions of genomic clones.
Construction of an rD15 expression clone (pUNCH 1235) and purification of
rD15 protein. Some of the details of our expression and purification of pUNCH
1235 are described elsewhere (20) and are therefore briefly described here. Our
strategy for construction of expression clone pUNCH 1235 was identical to that
used for pUNCH 1215, but it used correct homologous H. ducreyi primers (after
we had obtained genomic sequence). Primers were designed with unique restric-
tion sites for in-frame fusion to the expression plasmid pET30a with an N-
terminal hexahistidine leader sequence (20). The primers were 59-GGATCCG
AATTCGCACCATTTGTAGTAAAAGAT) and 39-CGCCGGCGTTCGAAT
TAGAATGTGCTGCCAACTG. The first amino acid of pUNCH 1235 was the
N terminus of the mature protein, and the final amino acid was the terminal
phenylalanine. PCR products were ligated into plasmid pCRII and transformed
into E. coli DH5aMCR. At least four white colonies containing the appropriate-
size insert were selected. Inserts were removed following digestion with appro-
priate restriction endonucleases, pooled, and ligated into pET30a that had been
cut with the same enzymes. After transformation into E. coli [(BL21(DE3)pLysS
or Nova Blue (DE3)]) and induction, several transformants were analyzed in
Western blots probed with affinity-purified anti-D15 peptide IgG to identify
clones expressing full-length product (20).
Since expression clone pUNCH 1235 lacked its native signal peptide, induction
of expression resulted in the accumulation of rD15 into inclusion bodies as
described by Qi et al. (42). We followed the general method for purification of
inclusion bodies proposed by Qi et al. (42). pUNCH 1235, which contained a
vector hexahistidine leader fused to the N terminus, enabled us to further purify
the protein by metal chelate chromatography under denaturing conditions (6 M
urea) as described by the manufacturer and as modified by us previously (20). We
attempted to renature purified recombinant protein slow reduction of urea
concentration. The protein was first diluted to 1 mg/ml, and the urea concen-
tration was reduced to 2 M. Zwittergent 3,14 was added to 5%, and the urea was
gradually removed by dialysis against phosphate-buffered saline (PBS) contain-
ing decreasing amounts of urea over several days at 4°C until no urea was
present.
Vaccine trials using rD15 in the TDRM of H. ducreyi infection. We used the
temperature-dependent rabbit model (TDRM) of H. ducreyi infection as first
described by Hansen et al. (25) and as previously modified by our group (12).
Eight-week-old New Zealand White rabbits (supplied by Charles River Inc.;
weighing approximately 1.5 kg when first vaccinated) were immunized twice, 4
weeks apart, using rD15-His tag immunogen in Zwittergent 3,14 or in 350 ml of
PBS or 100 mg of rFetA as a control. The first dose was in Freund’s complete
adjuvant, and the second was in Freund’s incomplete adjuvant. In both immu-
nizations, half of the dose was given intramuscularly and the other half was given
subcutaneously. Rabbits were bled for serologic assays at weeks 0, 2, 4, 6, and 8
from the first immunization and after infection at 8 weeks. During the 2-week
period between weeks 6 and 8, the rabbits were acclimatized to a temperature of
15°C. The day before infection, the backs of the rabbits were shaved. The
following day, the rabbits were intradermally inoculated with 105 to 103 CFU of
broth-grown mid-log-phase H. ducreyi strain 35000 in triplicate. Every second day
for a period of 20 days, two lesions from each inoculum size were scored
macroscopically on a scale of 0 to 4 (0, nil; 1, erythema; 2, induration; 3,
suppuration; and 4, ulcer), while the third lesion was cultured by sidewise aspi-
ration of the lesion for the presence of H. ducreyi. All measurements were
conducted by an operator blinded to the immunization group or status of the
individual animal.
Immunological studies. Enzyme-linked immunosorbent assays (ELISAs) and
Western blotting were performed as previously described (16). Protein A-alka-
line phosphatase was used as the secondary conjugate. p-Nitrophenol phosphate
and 5-bromo-4-chloro-3-indolylphosphate–nitroblue tetrazolium (BCIP-NBT)
substrates were used for development of ELISAs and Western blots, respec-
tively.
Whole-cell binding assays. Whole-cell dot blots were performed using choc-
olate agar-grown H. ducreyi strain 35000 for the antigen as previously described
(16), with the following modifications. H. ducreyi (optical density 5 0.2 at 600
nm) was suspended in PBS containing Ca and Mg supplements (the 1003 stock
contains, per liter, 2.1 g of MgCl2, 1.7 g of CaCl2, and 0.7 g of MgSO4); 100 ml
of this bacterial suspension was briefly suctioned onto a nitrocellulose membrane
(Nitroplus; Osmonics, Inc.). All subsequent incubations were performed under
gentle agitation. The membrane was blocked in 2% bovine serum albumin for 15
min, and primary antibody dilutions were applied for 1 h. After three 5-min
washes in PBS-Tween (0.05%), protein A-alkaline phosphatase conjugate (1:
5,000; Sigma) was applied for 1 h. After washing again as described above, the
substrate BCIP–NBT was added for development without shaking.
Bactericidal assays. To measure the ability of anti-rD15 antibodies to elicit a
bactericidal response, bactericidal assays were performed as previously described
(16). Briefly, chocolate agar-grown bacteria were diluted in GCB broth to con-
tain approximately 2,000 CFU/ml. Preimmune or postimmune sera from the
rabbits represented in Fig. 5 were pooled for use in bactericidal assays. These
sera were mixed with the bacteria in a total volume of 100 ml in a microtiter dish.
After 15 min of incubation with heat-inactivated rabbit anti-rD15 antibody, 10 ml
of complement-intact, pooled normal human serum (NHS; approximately 10%,
final concentration) or normal rabbit serum (10%; Pel Freeze Biological, Rogers,
Ark.) (27) was added, and incubation continued for 30 min. Controls included no
rabbit antibody (to control for preimmune killing). Controls for complement
activity in the NHS included testing the complement source (serum) against
serum-susceptible organisms (H. ducreyi dsrA mutant FX517) (18). Controls
using heat-inactivated NHS (complement source) were done to determine if a
reduction in CFU was the result of agglutination by antibody.
Nucleotide sequence ascession number. The DNA sequence of the H. ducreyi
D15 gene has been assigned GenBank accession number AF329831.
RESULTS
Identification of a D15 protein from H. ducreyi. During an
unrelated study to search for TonB-dependent outer mem-
brane receptor proteins, several proteins in the range of 70 to
100 kDa were subjected to N-terminal amino acid sequencing.
The sequence obtained for a protein of approximately 85 kDa
was similar to the sequence of protective antigens described for
H. influenzae and P. multocida. Like H. ducreyi, these two
related bacteria are members of the family Pasteurelleaceae.
An antipeptide serum to the N-terminal amino acid sequence
of the H. ducreyi protein was prepared, and all tested strains of
H. ducreyi expressed an immunoreactive protein of mobility
similar to that of the D15 protein of strain 35000 (34 strains
[data not shown]). Therefore, based on these data, we chose to
study the D15 protein from H. ducreyi at the molecular level
and to determine its potential as a vaccine candidate.
Cloning and sequencing of the D15 gene. Initially, we used
degenerate and heterologous primers in PCR to amplify,
clone, and sequence a 2.4-kb gene encoding the D15 protein
from H. ducreyi strain 35000 (pUNCH 1215 [Table 1]).
FIG. 2. Comparison of the H. ducreyi D15 amino acid sequence with D15 sequences from other Pasteurellaceae. The mature coding region of
the H. ducreyi D15 protein was analyzed using the program Pretty Box. Identical sequences are shaded and boxed. H. ducr, H. ducreyi strain 35000;
H. influ, H influenzae type B strain CA; P. mult, P. multocida strain PM70. Three variable regions for the H. ducreyi D15 protein are underlined.
VOL. 69, 2001 85-kDa OUTER MEMBRANE PROTEIN FROM H. DUCREYI 4441
pUNCH 1215 was fused with an N-terminal leader sequence
from the vector. After induction with IPTG, an immunoreac-
tive protein was produced which migrated slightly more slowly
(as expected due to the hexahistidine leader fusion) than did
native D15 from H. ducreyi (data not shown). We further
confirmed that we had cloned a D15 gene by sequencing
pUNCH 1215 and comparing the sequence to those of other
D15 genes. We then used pUNCH 1215 to obtain two genomic
EcoRI clones spanning approximately 13 kb of DNA which
included all of the D15 gene and flanking DNA (Fig. 1).
The DNA sequence for the H. ducreyi D15 gene contained
an open reading frame (ORF) of 2,382 bp and predicted a
protein of 794 amino acids. A putative ribosome-binding site
(AGGA) was separated by 8 nucleotides from the D15 ATG
initiation codon. The deduced amino acid sequence revealed a
17-amino-acid N-terminal leader sequence. The VXA se-
quence resembled a signal peptidase I cleavage site, and our
Edman degradation data confirmed cleavage. Cleavage at this
site would yield a mature protein of 86,915 Da, which is in
agreement with the migration of native D15 from outer mem-
branes subjected to SDS-polyacrylamide gel electrophoresis.
Concordant with outer membrane localization, D15 contained
a carboxyl-terminal motif ending with a phenylalanine, which is
found in the majority of integral outer membrane proteins
(50). A search of databases with the D15 sequence identified
several similar proteins from other pathogenic bacteria, includ-
ing P. multocida, H. influenzae, Neisseria gonorrhoeae, N. men-
ingitidis, E. coli, Shigella dysenteriae, and Brucella abortus. The
H. ducreyi D15 protein is most similar to the other members of
the Pasteurellaceae for which there is sequence available. Com-
pared to the H. ducreyi D15 protein, the P. multocida strain
PM70 protein (http://www.ncbi.nlm.nih.gov/Micro_blast/unfin
ishedgenome.html) was 66% similar and 56% identical,
whereas the H. influenzae type B strain CA protein (22) was
63% similar and 50% identical (Fig. 2).
A short intergenic region (49 nucleotides) separated the
D15 ORF from the upstream ORF and contained no obvious
promoter. The upstream ORF (Fig. 1) was very similar to a
protein (ORF HI 918) of unknown function. A 102-bp inter-
genic region between D15 and the downstream ORF con-
tained a 14-base inverted repeat with 12 exact matches, which
may represent a transcriptional terminator. Downstream of
D15 were two ORFs similar to skp and firA described for P.
multocida (11).
D15 expression in E. coli. Although we had already con-
structed expression clone pUNCH 1215, it had been made with
degenerate, heterologous primers. Therefore, we recon-
structed a plasmid equivalent to pUNCH 1215, but using the
appropriate primers to form pUNCH 1235. After induction of
rD15 protein and its purification from E. coli on a nickel
column, the rD15-His protein was putatively refolded. The
final purified rD15-His protein used for rabbit challenge ex-
periments was analyzed for purity by SDS-PAGE (Fig. 3A,
lane 2). It should be noted that the larger size of the recom-
binant protein in lane 2 is consistent with the presence of a
hexahistidine leader in this form of rD15. The antigenicity of
the rD15-His protein was analyzed by Western blotting using
the independently derived affinity-purified anti-D15 synthetic
peptide IgG as the primary antibody (Fig. 3B, lane 2).
Immunization with rD15-His modifies the course of a ho-
mologous challenge infection in the TDRM of H. ducreyi in-
fection. We used the TDRM to test the vaccine potential of
rD15-His, in four groups of nine rabbits, including parallel
controls. By chance, challenge inoculum titers were slightly but
significantly higher in test-versus sham-immunized control an-
imals (Table 1). Nevertheless, for inocula from 103 to 105 CFU
(in 100 ml), the lesion score and size (Fig. 4), cumulative size,
and proportion of rabbits that developed ulcers (Table 1) were
slightly lower for the rD15-immunized rabbits than the sham-
immunized rabbits. Duration of culture positivity (Table 1) was
reduced by 2 to 3 days in rD15-immunized rabbits (P , 0.05 at
105 CFU). Similarly, the duration of ulcers (Table 1) was
reduced by up to 4 days (P , 0.05 at 104 and 105 CFU). A
negative control immunogen, rFetA-His, was used to seek a
nonspecific effect of immunization with an irrelevant protein,
expressed and purified from the same system as rD15-His. No
pattern of differential virulence was observed between this
group and sham-immunized rabbits (Fig. 4 and Table 1).
Immune response to rD15 from the rabbit challenge exper-
iments. The immune response to the rD15-His from the rabbit
challenge experiments was analyzed for specificity and assessed
semiquantitatively. Rabbit antiserum, obtained after two im-
munizations but before the challenge infection (8 weeks), was
specific for the SDS-denatured form of the D15 protein in
Western blots of H. ducreyi outer membranes (Fig. 5).
ELISAs were performed using two different antigens. The
first ELISA used purified rD15-His as the coating antigen, and
the optical densities of the postimmune sera (1:1,000) from
these rabbits varied between 0.640 and 2.145. In contrast, the
FIG. 3. SDS-PAGE (A) and Western blot analysis (B) of H. ducreyi
outer membrane proteins and purified recombinant proteins. (A) H.
ducreyi outer membrane proteins prepared from strain 35000 or re-
combinant His-tagged proteins purified from E. coli as described in the
text were solubilized at 100°C for 5 min under reducing conditions.
After electrophoresis, the gel was stained with Coomassie blue. Lanes:
1, H. ducreyi outer membrane proteins (30 mg, heme limiting); 2,
purified rD15-His (2 mg) from pUNCH 1235; 3, molecular weight
standards. (B) Western blot of H. ducreyi outer membrane proteins
and D15 proteins. Five micrograms of H. ducreyi outer membrane
protein or 500 ng of recombinant protein was loaded in each lane of an
SDS–10% polyacrylamide gel. Lane numbers correspond to those in
panel A. After electrotransfer, D15 proteins were detected with affin-
ity-purified anti-D15 peptide IgG.
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second ELISA used outer membrane protein purified from
strain 35000 as the coating antigen, and the postimmune op-
tical densities were all less than 0.1 at the same dilution. Op-
tical densities for preimmune sera were all less than 0.05.
When these sera were tested for binding to whole cells in dot
blots, we found that binding was weak or negative (data not
shown). Significantly, some PBS (sham)-immunized rabbits ap-
peared to have a similar weak rise in titer in dot blots, sug-
gesting that the increase in binding was not due to D15 immu-
nization.
Bactericidal assays. The ability of antisera to direct comple-
ment-mediated killing of H. ducreyi was tested in bactericidal
FIG. 4. Immunization with rD15 modifies the course of a homologous challenge infection in the temperature-dependent rabbit model of H.
ducreyi infection. Rabbits were vaccinated twice with 100 mg of rD15-His (n 5 13) rFetA-His (n 5 8) or sham were vaccinated with 350 ml of PBS
(n 5 14) as described in the text. Four weeks after the second vaccination, rabbits were challenged intraepithelially with 103 CFU of H. ducreyi
strain 35000 in 100 ml of PBS. Lesion score (A) and lesion size (B) of rabbits vaccinated with rD15-His (gray boxes and gray bars) and rFetA-His
(inverted white triangles and white hatched bars) are compared to those of controls (black circles and black bars) (scored as 0 [nil], 1 [erythema],
2 [papule], 3 [pustule], and 4 [ulceration]). Data from rD15- and rFetA-immunized rabbits were compared to data from sham-immunized controls
by an analysis of variance.
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assays. As sources of complement, we used either NHS or
normal rabbit serum, previously tested for complement activ-
ity. We observed no killing of H. ducreyi by serum at the tested
dilutions (between 1:10 and 1:500 [data not shown]) in either
the pre- or postimmune specimens.
Conservation of D15 in H. ducreyi. Western blot of analyses
of geographically diverse strains were undertaken to examine
the conservation of D15 expression and conservation of D15
antigenicity. We used the anti-peptide D15 IgG (34 strains
[Fig. 6 and data not shown]), and all tested strains made an
immunoreactive protein. The migration patterns of the D15
bands were very similar or indistinguishable, suggesting a high
degree of amino acid conservation in the D15 proteins from
unrelated strains.
DISCUSSION
In this study, we identified an 85-kDa outer membrane pro-
tein in H. ducreyi which shows significant similarity to a protein
found in several other pathogenic bacteria. This protein was of
interest because it has been shown to be protective in animal
models of infection in two other bacterial systems.
Overall the structure of the H. ducreyi, H. influenzae, and P.
multocida D15 or D15-like proteins were conserved; however,
it should be noted that small interspecies variable regions were
present in the three proteins (Fig. 2). Compared to the other
two species, three H. ducreyi variable regions resided in the
C-terminal one-third of the protein (Fig. 2). The first H. ducreyi
variable region was 16 amino acids long and contained an
insertion of 6 or 7 amino acids compared to the P. multocida or
H. influenzae protein, respectively. Interestingly, the next two
H. ducreyi interspecies variable regions are in the identical
positions of the interstrain H. influenzae D15 variable regions
previously described by Loosmore et al. (33). In variable re-
gions 2 and 3 of the H. ducreyi sequence, there were deletions
of five and six amino acids, respectively, compared to H. influ-
enzae and P. multocida. Other studies of integral outer mem-
brane proteins have suggested that variation in surface-ex-
posed portions (loops) is driven by immunologic pressure.
However, in Western blots of 34 geographically diverse strains
of H. ducreyi, a D15 protein of approximately the same molec-
ular mass was observed, suggesting a high degree of interstrain
conservation. Nevertheless, understanding the variability of H.
ducreyi D15 will require additional sequencing of the D15
genes from other strains.
The region surrounding the D15 gene in H. ducreyi was very
similar to the D15 region of H. influenzae Rd (22). The H.
influenzae Rd D15 ORF is assigned number HI 917. We iden-
tified an ORF upstream of the H. ducreyi D15 (similar to Rd
HI 918) and two downstream (similar to Rd HI 916 and 915).
HI 916 and 915 show similarity to Skp and FirA from P.
multocida (12). Skp has been implicated as a molecular chap-
erone (10, 48), whereas FirA has been shown to be an acyl-
transferase required for lipid A biosynthesis (29, 43). Further-
more, Skp is a protective antigen in H. influenzae (31). The
short intergenic sequence between the upstream gene (49 bp)
and the start codon for D15, along with the lack of obvious
promoter sequence, suggests the possibility that D15 is part of
a single transcriptional unit driven from a yet to be identified
promoter.
Attempts to construct isogenic D15 mutants were unsuccess-
ful. The first technique tried was allelic replacement (23),
which had been successful in our laboratory for three H. du-
creyi genes previously (17, 19, 51). The second mutagenesis
procedure, which we have also used previously (18), was de-
scribed by Bozue et al. (7). D15 mutants have not been re-
ported from any of the organisms studied to date, suggesting
that D15 may be necessary for the viability of gram-negative
bacteria, perhaps by affecting expression or function of other
vital genes. Construction of nonpolar and/or conditional D15
mutants will be critical to studies of the function and signifi-
cance of D15.
Some data suggest that H. ducreyi D15 might be a vaccine
candidate, whereas other data contradict this notion. D15 and
related proteins have been shown to be protective antigens (21,
33, 44, 56). Our studies using the rabbit model of infection
suggested that we were able to modify the course of an infec-
tion by immunizing with rD15-His. Although we were not able
to completely prevent disease or infection, our results are not
substantially different from those of three previous studies
FIG. 5. Western blots of immune response to rD15. A preparative
SDS-polyacrylamide gel containing 25 mg of H. ducreyi outer mem-
brane proteins was electrophoresed and electroblotted to nitrocellu-
lose. After blocking, the membrane was placed in a Miniprotean Mul-
tiScreen apparatus and probed with representative anti-rD15 rabbit
antisera obtained after two immunizations with rD15-His, but before
the challenge with strain 35000 (1:1,000 dilution). Protein A-alkaline
phosphatase and BCIP-NBT were used for detection of bound immu-
noglobulins. Lane 1, pooled preimmune serum; lanes 2 to 7, postim-
mune serum from rabbits 7, 8, 9, 76, 77, 78, 79, respectively; lane 8,
affinity-purified anti-peptide IgG; lane 9, no primary antibody. The
preimmune sera were pooled in this experiment; in other experiments
using individual preimmune sera, no reaction was observed (n 5 3). No
reactivity was noted in mock-immunized rabbits (data not shown).
FIG. 6. D15 protein is expressed and immunologically conserved in
H. ducreyi. Protein from each indicated H. ducreyi strain (approximate-
ly 5 3 107 CFU or 15 mg per lane) was subjected SDS-PAGE and
electroblotting using the affinity-purified anti-peptide D15 IgG. Lanes:
1, 35000; 2, CIP542; 3, 4V; 4, 26V; 5, C110; 6, 2753; 8, 90–244.
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using outer membranes (25), pilin (12), or hemolysin (14) from
H. ducreyi as immunogens. These rabbit experiments in induc-
ible immunity differ from others reported in the blinding of the
observer to the interventions, which may reduce biased obser-
vation, but at the expense of the apparent effect. Results of
immunological studies indicate that H. ducreyi D15 is well
conserved. A synthetic peptide based on D15 and rD15 pro-
teins were immunogenic in rabbits. rD15 is readily produced in
E. coli, where it can be induced to 50% of the total cellular
protein. rD15 was readily purified, and it demonstrated partial
protection from a homologous challenge. In humans, the D15
protein is apparently expressed in vivo, since an earlier study
detected the presence of antibodies in humans (20).
However, neither the antibodies which we produced during
this study nor those present after natural human infection are
bactericidal. Indeed, the resistance of H. ducreyi to NHS or
hyperimmune serum is well known (13, 27). No strongly bac-
tericidal antibody against H. ducreyi has yet been reported (27).
Likewise, we were unable to demonstrate bactericidal activity
for anti-rD15 antibodies. Repeated infection with H. ducreyi is
fairly common in areas where chancroid is endemic. D15 an-
tibodies are produced after naturally occurring chancroid in-
fections (20) but apparently do not prevent subsequent infec-
tions. It is possible that the antibodies produced after
experimental immunization of animals or natural chancroid
disease do not contain the proper characteristics that would
lead to protection. Perhaps the antibodies are of low affinity or
to the wrong D15 epitopes, they do not fix complement prop-
erly, or they do not lead to opsonophagocytic killing, none of
which were measured in this study. Whether antibodies or a
cellular response mediate the partial protection shown here in
rabbits is not known. However, the lack of binding of antibod-
ies to whole cells from rabbits immunized with rD15 suggest
that a cellular immune response was responsible for protec-
tion, as has been suggested by another study using a different
antigen (13). Alternatively, it might be that additional immu-
nizations would generate antibodies which recognize D15 on
whole cells. Additional rabbit challenge studies are required to
clarify these issues. It should be noted that in the H. influenzae
system, rD15 or passively transferred anti-rD15 antibodies pro-
tected in animal models of infection; however, these sera dem-
onstrated only variable, inconsistent bactericidal activity (33).
Thus, further studies with H. ducreyi D15 may clarify these
vaccine issues and determine the function of this interesting
protein.
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